|
|
|
|
|
Highlights from the 2024 ASCO Genitourinary Cancers Symposium |
|
|
|
|
| Disparities in Prostate Cancer Mortality and Clinical Trial Availability Across Vulnerable Populations |
| Rishi Sekar, MD |
| Rishi Sekar presented findings on disparities in prostate cancer mortality and clinical trial availability across vulnerable populations. The study utilized custom data linkage from ClinicalTrials.gov, SEER Registry, and the Centers for Disease Control and Prevention Social Vulnerability Index. The analysis, based on county-level data, revealed significant geographic disparities in prostate cancer clinical trial availability in the United States. |
|
|
|
|
|
| Impact of Race on Outcomes to 177-Lu-PSMA-617 for mCRPC |
| Avina Rami |
| Avina Rami presented findings on the impact of race on outcomes to 177-Lu-PSMA-617 (LuPSMA) for mCRPC. The study included patients from two academic medical centers in Boston, MA, who received at least two cycles of LuPSMA. The analysis focused on self-reported race, categorizing African American, Hispanic/Latino, and Asian patients as minorities. |
|
|
|
|
|
| 3TMPO: Prognostic Value of FDG, PSMA, and DOTATATE Uptake on PET Imaging in mCRPC |
| Frederic Pouliot, MD, Ph.D. |
| Frederic Pouliot presented findings from the 3TMPO study, a prospective trial in metastatic castration-resistant prostate cancer patients undergoing up to three PET tracers (68Ga-PSMA-617, 18F-FDG, and 68Ga-DOTATATE). This study aimed to assess the prognostic value of FDG+/PSMA- lesions and DOTATATE+ lesions. |
|
|
|
|
|
| Assessing the Clinical Utility of Rapid Post-Therapy Whole-Body Digital SPECT/CT in Evaluating Early Treatment Response of 177Lu-PSMA-617 Treatment |
| Hong Song, MD, Ph.D. |
| Hong Song presented findings on the clinical utility of rapid post-therapy whole-body digital SPECT/CT in evaluating early treatment response to 177Lu-PSMA-617 for mCRPC. Quantitative analysis revealed that a >30% decrease in Lu-PSMA positive total tumor volume on early follow-up SPECT/CT was associated with longer overall survival and longer PSA progression-free survival. |
|
|
|
|
|
| Association Between SPECT/CT Total Tumor Volume and New Lesions in Early Cycles of 177Lu-PSMA-617 and PFS and OS in Men with mCRPC |
| Ridvan Arda Demirci |
| Ridvan Demirci presented findings on the association between SPECT/CT total tumor volume and the appearance of new lesions in early cycles of 177Lu-PSMA-617 and progression-free and overall survival in men with metastatic castration-resistant prostate cancer (mCRPC). The study, which included 66 patients, found that higher SPECT/CT total tumor volume at the second and third cycle, as well as the detection of new lesions at the second cycle, were associated with higher risks of progression and death. |
|
|
|
|
|
|
|
|
|
|
| Association Between PET-Based TheraP Eligibility and 177Lu-PSMA-617 Outcomes in VISION-Eligible Patients with mCRPC
|
| Ridvan Arda Demirci
|
| Ridvan Demirci presented findings on the association between PET-based TheraP eligibility and outcomes in VISION-eligible patients with metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617. The study included 75 patients, and those assessed as TheraP-ineligible had lower PSA50 responses compared to TheraP-eligible patients.
|
|
|
|
|
|
| Low- and High-Volume Disease in mHSPC, from CHAARTED to PSMA-PET: An International Multicenter Retrospective Study |
| Lena Unterrainer, MD |
| Lena Unterrainer presented findings on low- and high-volume disease in metastatic mHSPC, comparing CHAARTED definitions based on conventional imaging to PSMA-PET. The study included 67 pairs of PSMA PET/CT and bone scans, and results showed a shift in disease volume classification in 40.3% of patients when transitioning from conventional imaging to PSMA-PET. |
|
|
|
|
|
| Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in mCRPC
|
| Andrei Gafita, MD
|
| Andrei Gafita presented findings on the response evaluation criteria in PSMA PET/CT (RECIP 1.0) for mCRPC. The study aimed to assess the agreement between RECIP determined qualitatively by nuclear medicine physicians (visual RECIP) and RECIP determined using tumor segmentation software (quantitative RECIP). The results showed excellent inter-reader reliability and agreement between visual RECIP and quantitative RECIP.
|
|
|
|
|
|
| Prognostic Value of AI–Driven Tumor Estimation of PSMA PET Total Tumor Burden in Newly Diagnosed High-Volume mHSPC |
| Francisco Osvaldo Garcia-Perez, MD |
| Francisco Osvaldo Garcia-Perez presented findings on the prognostic value of artificial intelligence–drive tumor estimation of PSMA PET total tumor burden in newly diagnosed high-volume mHSPC. The results showed that a lower PSMA total tumor burden was associated with shorter progression-free survival compared to a higher PSMA total tumor burden. |
|
|
|
|
|
| Real-World Comparison of PSA Response in Patients with mCSPC Treated with Apalutamide or Enzalutamide
|
| Benjamin Lowentritt, MD, FACS
|
| Benjamin Lowentritt presented a real-world comparison of PSA response in patients with mCSPC treated with apalutamide or enzalutamide. The study aimed to assess the PSA90 response, defined as a ≥90% decline in PSA relative to the most recent pre-index PSA, 6 months after initiating either apalutamide or enzalutamide. The results showed that a higher proportion of patients treated with apalutamide achieved a PSA90 response compared to those treated with enzalutamide.
|
|
|
|
|
|
|
|
|
|
|
| Real-World Treatment Sequences and Time to Discontinuation in the First-Line mCRPC Setting |
| Emily Smyth, PharmD, BSPharm |
| Emily Smyth presented a study on real-world treatment sequences and time to discontinuation in the first-line metastatic castration-resistant prostate cancer setting. The study, conducted using data from the nationwide Flatiron Health EHR-derived database, aimed to analyze treatment patterns, time to discontinuation, and time to chemotherapy for first-line mCRPC patients. |
|
|
|
|
|
| Remote Delivery of Cancer Genetic Testing in Veterans with Metastatic Prostate Cancer: A Million Veteran Program Study |
| Robert B. Montgomery, MD |
| Robert Montgomery presented a study on the remote delivery of cancer genetic testing in veterans with metastatic prostate cancer. The study aimed to assess the uptake of germline testing using a remote, VA system-wide approach in veterans who participated in the Veterans Administration Million Veteran Program (MVP). |
|
|
|
|
|
| OASIS: Survival Outcomes of Apalutamide as a Starting Treatment - Impact in Real-World Patients with mCSPC
|
| Benjamin Maughan, MD, PharmD
|
| Benjamin Maughan presented a study on the survival outcomes of apalutamide as a starting treatment for patients with mCSPC in the real world. The retrospective cohort study, based on the ConcertAI Real World Database 360 prostate cancer dataset, evaluated clinical outcomes in patients with newly diagnosed mCSPC from January 1, 2018, to September 30, 2022.
|
|
|
|
|
|
| Evaluating Clinical Outcomes with Systemic Therapy Given After Progression on PSMA Radioligand Therapy in Patients with mCRPC |
| Soumaya Labidi, MD |
| Soumaya Labidi presented a retrospective cohort study on clinical outcomes with systemic therapy given after the progression of PSMA radioligand therapy in patients with mCRPC. The study suggested that responses to the next line of therapy after progressing on PSMA radioligand therapy are rare, with PSA levels being prognostic in this context. Further prospective trials are needed to determine the optimal sequencing of PSMA radioligand therapy and taxanes in mCRPC. |
|
|
|
|
|
| Implementation Outcomes of a Multidisciplinary Approach for Lu177-PSMA-617 Therapy |
| Marybeth Nedrud, MD, Ph.D. |
| Marybeth Nedrud presented outcomes from the implementation of a multidisciplinary approach for Lu177-PSMA-617 (LuPSMA) therapy. The results showed that the median number of treatments was 4.0, with 41% receiving all 6 planned treatments. During treatment, 16% experienced a treatment hold, and 8% had dose reductions. Early discontinuation primarily occurred due to clinician-assessed progression or cytotoxicity. |
|
|
|
|
|
| Patient Outcomes After Therapy with 177Lu-PSMA-617 for mCRPC: A Tertiary Center Experience |
| Praful Ravi, MB, BChir, MRCP |
| Praful Ravi presented findings on patient outcomes after therapy with 177Lu-PSMA-617 (LuPSMA) for mCRPC. The study included 96 patients at the Dana-Farber Cancer Institute who received LuPSMA between June 2022 and July 2023. Of these patients, 18 completed all 6 cycles, 35 discontinued prior to cycle 6 due to progressive disease, 10 died mid-treatment, and 33 were midway through treatment. |
|
|
|
|
|
|
